%PDF-1.4
%
51 0 obj
<>
endobj
48 0 obj
<>
endobj
120 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-09-13T14:03:47Z
2024-03-29T06:15:01-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T06:15:01-07:00
application/pdf
Heather
2003-801.oct.X
uuid:1e71d81f-1dd2-11b2-0a00-d60927bd7700
uuid:1e71d822-1dd2-11b2-0a00-900000000000
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
52 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
138 0 obj
[142 0 R]
endobj
139 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc -0.0266 Tw 10 0 0 10 43 731.1616 Tm
[(functional properties correlate with L)91.7 (V)-205.6 (systolic and diastolic)]TJ
0.0096 Tw 0 -1.2 TD
(measures, but are independent of pulmonary artery pressure)Tj
0.19209 Tw T*
(and pulmonary fibrosis, and thus may represent an early)Tj
0.01489 Tc 0.36 Tw T*
[(marker of intrinsic myocardial involvement. )17.5 (W)79.8 (e also)]TJ
-0.00011 Tc 0.1694 Tw T*
[(showed that the CCB, nicardipine, mitigates R)79.7 (V)-401.6 (function)]TJ
0.0639 Tw T*
[(abnormalities, as previously shown for L)91.7 (VEF)79.7 (. Study of the)]TJ
0.2916 Tw T*
[(longterm significance of R)79.7 (V)-523.9 (dysfunction and ef)17.7 (fects of)]TJ
0.02499 Tw T*
(calcium channel blockers is warranted. )Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 50 613.1616 Tm
[(1.)-875.1 (D\325Angelo )17.7 (W)110.9 (A, Fries JF)79.7 (, Masi )54.8 (A)110.8 (T)74 (, Schulman LE. Pathologic )]TJ
1.675 -1.25 Td
(observations in systemic sclerosis \(scleroderma\): a study of )Tj
0 -1.25 TD
[(fifty-eight autopsy cases and fifty-eight matched controls. )54.8 (Am )]TJ
0 Tc T*
(J Med 1969;46:428-40.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (Bulkley BH, Ridolfi RL, Salyer )17.7 (WR, Hutchins GM. Myocardial)]TJ
1.675 -1.25 Td
(lesions of progressive systemic sclerosis: a cause of cardiac)Tj
T*
(dysfunction. Circulation 1976;53:483-90.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Kahan )54.8 (A, Devaux JY)128.8 (, )54.8 (Amor B, et al. Nifedipine and thallium-201)]TJ
1.675 -1.25 Td
(myocardial perfusion in progressive systemic sclerosis. N Engl )Tj
0 Tc T*
(J Med 1986;314:1397-402.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Follansbee )17.7 (WP)110.7 (, Curtiss EI, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, et al. Physiologic )]TJ
1.675 -1.25 Td
(abnormalities of cardiac function in progressive systemic sclerosis)Tj
T*
[(with dif)17.7 (fuse scleroderma. N Engl J Med 1984;310:142-8.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Candell-Ria J, )54.8 (Armadans-Gil L, Sime\227n CP)110.7 (, et al. Comprehensive)]TJ
1.675 -1.25 Td
(noninvasive assessment of cardiac involvement in limited systemic)Tj
T*
[(sclerosis. )54.8 (Arthritis Rheum 1996;39:1)36.8 (138-45.)]TJ
0 Tc -1.675 -1.25 Td
[(6.)-875 (Medsger )17.7 (T)80 (A, Masi )54.8 (A)110.9 (T)74.1 (, Rodnan GP)110.9 (, Benedek )17.7 (TG, Robinson H.)]TJ
-0.00011 Tc 1.675 -1.25 Td
(Survival with systemic sclerosis \(scleroderma\): a life-table analysis)Tj
T*
[(of clinical and demographic factors in 309 patients. )54.8 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
(1971;75:370-6.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Steen )17.7 (VD, Follansbee )17.7 (WP)110.7 (, Conte CG, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)54.8 (. )17.7 (Thallium)]TJ
1.675 -1.25 Td
(perfusion defects predict subsequent cardiac dysfunction in patients)Tj
T*
[(with systemic sclerosis. )54.8 (Arthritis Rheum 1996;39:677-81.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (James )17.7 (TN. De subitaneis mortibus. )17.7 (VIII. Coronary arteries and)]TJ
1.675 -1.25 Td
(conduction system in scleroderma heart disease. Circulation)Tj
0 Tc 0 Tw T*
(1974;50:844-56.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Kahan )54.8 (A, Nitenber)17.7 (g )54.8 (A, Foult JM, et al. Decreased coronary reserve)]TJ
1.675 -1.25 Td
[(in primary scleroderma myocardial disease. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1985;28:637-46.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Alexander EL, Firestein GS, )17.7 (W)79.9 (eiss JL, et al. Reversible )]TJ
2.175 -1.25 Td
(cold-induced abnormalities in myocardial perfusion and function in)Tj
T*
[(systemic sclerosis. )54.8 (Ann Intern Med 1986;105:661-8.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (E)0.1 (llis )17.7 (WW)91.7 (, Baer )54.8 (AN, Robertson RM, Pincus )17.7 (T)74 (, Kronenber)17.7 (g MW)91.7 (.)]TJ
2.1381 -1.25 Td
(Left ventricular dysfunction induced by cold exposure in patients)Tj
T*
[(with systemic sclerosis. )54.8 (Am J Med 1986;80:385-92.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Kahan )54.7 (A, Devaux JY)128.8 (, )54.7 (Amor B, et al. Pharmacodynamic ef)17.7 (fect of)]TJ
2.175 -1.25 Td
(nicardipine on left ventricular function in systemic sclerosis. )Tj
T*
(J Cardiovasc Pharmacol 1990;15:249-53.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Duboc D, Kahan )54.8 (A, Maziere B, et al. )17.7 (The ef)17.7 (fect of nifedipine on)]TJ
2.175 -1.25 Td
[(myocardial perfusion and metabolism in systemic sclerosis. )54.8 (A)]TJ
T*
[(positron emission tomographic study)64.8 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1991;34:198-203.)Tj
-0.00011 Tc 0.02499 Tw 30.825 66.171 Td
[(14.)-875.1 (Bewley )54.8 (AP)110.8 (, Cooper JP)110.7 (, Levell NJ, )17.7 (W)79.9 (alker JM, Dowd PM. Systemic)]TJ
2.175 -1.25 Td
[(sclerosis associated with right ventricular cardiomyopathy)64.8 (. Br )]TJ
T*
[(J Dermatol 1996;134:1)36.8 (141-3.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Giunta )54.8 (A, )17.7 (T)35 (irri E, Maione S, et al. Right ventricular diastolic )]TJ
2.175 -1.25 Td
(abnormalities in systemic sclerosis. Relation to left ventricular)Tj
T*
[(involvement and pulmonary hypertension. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:94-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (LeRoy C, Black C, Fleischmajer R, et al. Scleroderma \(systemic)]TJ
2.175 -1.25 Td
(sclerosis\). Classification, subset and pathogenesis. J Rheumatol)Tj
0 Tc 0 Tw T*
(1988;15:202-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Kaul S, Boucher CA, Okada RD, Newell JB, Strauss HW)91.7 (, Pohost)]TJ
2.175 -1.25 Td
(GM. Sources of variability in the radionuclide angiographic )Tj
T*
(assessment of ejection fraction: a comparison of first-pass and)Tj
T*
[(gated equilibrium techniques. )54.8 (Am J Cardiol 1984;53:823-8.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Polak JF)79.7 (, Kemper )54.8 (AJ, Bianco JA, Parisi )54.8 (AF)79.7 (, )17.7 (T)69.9 (ow DR. Resting early)]TJ
2.175 -1.25 Td
(peak diastolic filling rate: a sensitive index of myocardial )Tj
T*
(dysfunction in patients with coronary artery disease. J Nucl Med)Tj
0 Tc 0 Tw T*
(1982;23:471-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (De Groote P)110.7 (, Millaire )54.8 (A, Foucher)19.7 (-Hossein C, et al. Right ventricular)]TJ
2.175 -1.25 Td
(ejection fraction is an independent predictor of survival in patients)Tj
T*
[(with moderate heart failure. J )54.8 (Am Coll Cardiol 1998;32:948-54.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Di Salvo )17.7 (TG, Mathier M, Semigran MJ, Dec GW)91.7 (. Preserved right)]TJ
2.175 -1.25 Td
(ventricular ejection fraction predicts exercise capacity and survival)Tj
T*
[(in advanced heart failure. J )54.8 (Am Coll Cardiol 1995;25:1)36.8 (143-53.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Armstrong GP)110.8 (, )17.7 (Whalley GA, Doughty RN, et al. Left ventricular)]TJ
2.175 -1.25 Td
(function in scleroderma. Br J Rheumatol 1996;35:983-8.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Giunta )54.8 (A, )17.7 (T)35 (irri E, Maione, et al. Right ventricular diastolic )]TJ
2.175 -1.25 Td
(abnormalities in systemic sclerosis. Relation to left ventricular)Tj
T*
[(involvement and pulmonary hypertension. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:94-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Handa R, Gupta K, Malhotra )54.8 (A, et al. Cardiac involvement in)]TJ
2.175 -1.25 Td
(limited systemic sclerosis: non-invasive assessment in )Tj
T*
(asymptomatic patients. Clin Rheumatol 1999;18:136-9.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (V)110.8 (alentini G, )17.7 (V)59.8 (itale DF)79.7 (, Giunta )54.8 (A, Maione S, et al. Diastolic )]TJ
2.175 -1.25 Td
(abnormalities in systemic sclerosis: evidence for associated )Tj
T*
[(defective cardiac functional reserve. )54.8 (Ann Rheum Dis )]TJ
0 Tc 0 Tw T*
(1996;55:455-60.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (Fujimoto S, Kagoshima )17.7 (T)74 (, Nakajima )17.7 (T)74 (, Dohi K. Doppler )]TJ
2.175 -1.25 Td
(echocardiographic assessment of left ventricular diastolic function)Tj
T*
(in patients with progressive systemic sclerosis. Cardiology)Tj
0 Tc 0 Tw T*
(1993;83:217-27.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Brutsaert DL, Sys SU, Gillebert )17.7 (TC. Diastolic failure: )]TJ
2.175 -1.25 Td
[(pathophysiology and therapeutic implications. J )54.8 (Am Coll Cardiol)]TJ
0 Tc 0 Tw T*
(1993;22:318-25.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (Follansbee )17.7 (WP)110.7 (, Zerbe )17.7 (TR, Medsger )17.7 (T)79.9 (A. Cardiac and skeletal)]TJ
2.175 -1.25 Td
(muscle disease in systemic sclerosis \(scleroderma\): a high risk)Tj
T*
[(association. )54.8 (Am Heart J 1993;125:194-203.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Allanore )36.8 (Y)128.9 (, Borderie D, Meune C, et al. NT)91.7 (-pro-B-type brain )]TJ
2.175 -1.25 Td
(natriuretic peptide as a diagnostic marker of early pulmonary )Tj
T*
[(arterial hypertension and ef)17.7 (fects of calcium channel blockers in)]TJ
T*
[(systemic sclerosis. )54.8 (Arthritis Rheum 2003;48:3503-8.)]TJ
ET
0 0 0 1 K
43 72 m
547 72 l
S
BT
/T1_3 1 Tf
8 0 0 8 43.5 53.9844 Tm
[(Meune, et al: Reduced R)17.7 (VEF in SSc)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1945)Tj
ET
0 0 0 0 k
/GS0 gs
96.22 76.58 396.48 -10.83 re
f*
0.5 w
96.22 76.58 396.48 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
31 0 obj
<>stream
8;Z\7MfQZg%.jN!TRUTE)p*-[KGGujmHX'K.'=YL//S'8Iar7O&!+cgp=AprL.cF!
=k?]CZbZO9I9ac154:\,0>(UO^bM]UJRr+Nf&T_q[m9=&^or&8^jE8]8Y9\=>%n]p
Nh#.W&nfHX/;nR;:"pI;;DerIR.Fk#\k5k+A=q$VUB=Q)?G''QUbO)m)d9jt5meTq
'0.^tb>>,+6Su8sAKM_f'B&CW`X+2J@VV*[N%`sB;miX(N&Tbs
9g3^I:huTGAUEA=mtCqq?)0G=LX&0Hl?((7.3;ldKtCOqJ,$J9U8+;IFJ:OAj)VPA
7@Eibgn*J9!nHeA!5K-B"/iD+[NUhOfZDot`!BH$
2!]KT#t,1hAXnFF9K$d#hD+'&SGToNDZb$R]Ct`L2/('WjWBc;i<+'S4J.em%Q4M?JfU:KSQ_=1V/=
BK*t0eeV!dpm8@:99j.>V/Iir>RTRei58m/P=Z"p")-rB(~>
endstream
endobj
35 0 obj
[/Indexed/DeviceRGB 255 34 0 R]
endobj
34 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
109 0 obj
<>
endobj
59 0 obj
<>
endobj
67 0 obj
<>
endobj
55 0 obj
<>
endobj
98 0 obj
<>
endobj
125 0 obj
<>
endobj
54 0 obj
<>
endobj
93 0 obj
<>stream
HU{PSW7{ R:*"Z(.EQ"@@!